Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 689 results
Author Title Type [ Year(Desc)]
Filters: First Letter Of Last Name is M  [Clear All Filters]
2021
Ketas TJ, Chaturbhuj D, Portillo VMCruz, Francomano E, Golden E, Chandrasekhar S, Debnath G, Díaz-Tapia R, Yasmeen A, Kramer KD et al..  2021.  Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva.. Pathog Immun. 6(1):116-134.
Ketas TJ, Chaturbhuj D, Portillo VMCruz, Francomano E, Golden E, Chandrasekhar S, Debnath G, Díaz-Tapia R, Yasmeen A, Kramer KD et al..  2021.  Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva.. Pathog Immun. 6(1):116-134.
de Melo CSoares, Singh V, Myrick A, Simelane SB, Taylor D, Brunschwig C, Lawrence N, Schnappinger D, Engelhart CA, Kumar A et al..  2021.  Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action Studies.. J Med Chem. 64(1):719-740.
de Melo CSoares, Singh V, Myrick A, Simelane SB, Taylor D, Brunschwig C, Lawrence N, Schnappinger D, Engelhart CA, Kumar A et al..  2021.  Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action Studies.. J Med Chem. 64(1):719-740.
Moore JP.  2021.  Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy.. JAMA. 325(13):1251-1252.
Moore JP, Gounder CR.  2021.  Beta testing the monkey model.. Nat Immunol. 22(10):1201-1203.
Zhao N, Dong W, Kim H, Moallemian R, Lv J, Wang H, Zheng H, Wei F, Ma X.  2021.  Capping protein regulator and myosin 1 linker 3 regulates transcription of key cytokines in activated phagocytic cells.. Cell Signal. 78:109848.
Zhao N, Dong W, Kim H, Moallemian R, Lv J, Wang H, Zheng H, Wei F, Ma X.  2021.  Capping protein regulator and myosin 1 linker 3 regulates transcription of key cytokines in activated phagocytic cells.. Cell Signal. 78:109848.
Zainabadi K, Walsh KFrances, Vilbrun SCharles, Mathurin LDaniel, Lee MHee, Saito K, Mishra S, Ocheretina O, Pape JWilliam, Nathan C et al..  2021.  Characterization of Differentially Detectable Mycobacterium tuberculosis in the Sputum of Subjects with Drug-Sensitive or Drug-Resistant Tuberculosis before and after Two Months of Therapy.. Antimicrob Agents Chemother. 65(8):e0060821.
Zainabadi K, Walsh KFrances, Vilbrun SCharles, Mathurin LDaniel, Lee MHee, Saito K, Mishra S, Ocheretina O, Pape JWilliam, Nathan C et al..  2021.  Characterization of Differentially Detectable Mycobacterium tuberculosis in the Sputum of Subjects with Drug-Sensitive or Drug-Resistant Tuberculosis before and after Two Months of Therapy.. Antimicrob Agents Chemother. 65(8):e0060821.
Pandey S, Singh A, Yang G, d'Andrea FB, Jiang X, Hartman TE, Mosior JW, Bourland R, Gold B, Roberts J et al..  2021.  Characterization of Phosphopantetheinyl Hydrolase from Mycobacterium tuberculosis.. Microbiol Spectr. 9(2):e0092821.
Wang C, Hong TY, Wang Y, Peng G, Yu Y, Zhang J, Zhuo D, Zheng J, Ma X, Cui X.  2021.  Combining UBR5 and CD163+ tumor-associated macrophages better predicts prognosis of clear cell renal cell carcinoma patients.. Cancer Immunol Immunother. 70(10):2925-2935.
Honjo K, Russell RM, Li R, Liu W, Stoltz R, Tabengwa EM, Hua Y, Prichard L, Kornbrust AN, Sterrett S et al..  2021.  Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.. Cell Rep Med. 2(1):100164.
Honjo K, Russell RM, Li R, Liu W, Stoltz R, Tabengwa EM, Hua Y, Prichard L, Kornbrust AN, Sterrett S et al..  2021.  Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.. Cell Rep Med. 2(1):100164.
Honjo K, Russell RM, Li R, Liu W, Stoltz R, Tabengwa EM, Hua Y, Prichard L, Kornbrust AN, Sterrett S et al..  2021.  Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.. Cell Rep Med. 2(1):100164.
Zhan W, Zhang H, Ginn J, Leung A, Liu YJ, Michino M, Toita A, Okamoto R, Wong T-T, Imaeda T et al..  2021.  Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.. Angew Chem Int Ed Engl. 60(17):9279-9283.
Zhan W, Zhang H, Ginn J, Leung A, Liu YJ, Michino M, Toita A, Okamoto R, Wong T-T, Imaeda T et al..  2021.  Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.. Angew Chem Int Ed Engl. 60(17):9279-9283.
Zhan W, Zhang H, Ginn J, Leung A, Liu YJ, Michino M, Toita A, Okamoto R, Wong T-T, Imaeda T et al..  2021.  Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.. Angew Chem Int Ed Engl. 60(17):9279-9283.
Lee BShi, Hards K, Engelhart CA, Hasenoehrl EJ, Kalia NP, Mackenzie JS, Sviriaeva E, Chong SMin Sheril, Manimekalai MSony S, Koh VH et al..  2021.  Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.. EMBO Mol Med. 13(1):e13207.
Lee BShi, Hards K, Engelhart CA, Hasenoehrl EJ, Kalia NP, Mackenzie JS, Sviriaeva E, Chong SMin Sheril, Manimekalai MSony S, Koh VH et al..  2021.  Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.. EMBO Mol Med. 13(1):e13207.
Lee BShi, Hards K, Engelhart CA, Hasenoehrl EJ, Kalia NP, Mackenzie JS, Sviriaeva E, Chong SMin Sheril, Manimekalai MSony S, Koh VH et al..  2021.  Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.. EMBO Mol Med. 13(1):e13207.
Lee BShi, Hards K, Engelhart CA, Hasenoehrl EJ, Kalia NP, Mackenzie JS, Sviriaeva E, Chong SMin Sheril, Manimekalai MSony S, Koh VH et al..  2021.  Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.. EMBO Mol Med. 13(1):e13207.
Caniels TG, Bontjer I, van der Straten K, Poniman M, Burger JA, Appelman B, Lavell AHAyesha, Oomen M, Godeke G-J, Valle C et al..  2021.  Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination.. Sci Adv. 7(36):eabj5365.
Caniels TG, Bontjer I, van der Straten K, Poniman M, Burger JA, Appelman B, Lavell AHAyesha, Oomen M, Godeke G-J, Valle C et al..  2021.  Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination.. Sci Adv. 7(36):eabj5365.
Caniels TG, Bontjer I, van der Straten K, Poniman M, Burger JA, Appelman B, Lavell AHAyesha, Oomen M, Godeke G-J, Valle C et al..  2021.  Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination.. Sci Adv. 7(36):eabj5365.